Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT03477513 : Personalized Treatment of Glioblastoma Via Image-Guided Predictive Modeling of Recurrence: A Single-Arm, Single Institutional Pilot Prospective Study of Dose-Escalated Radiation Therapy
PhaseN/A
AgesMin: 18 Years Max: N/A
Eligibility
Inclusion Criteria:

- Patients with biopsy-proven WHO Grade IV glioblastoma, after gross-total or near-total
resection, who are undergoing definitive chemoradiation as part of their treatment
regimen

- Age 18 or older

- Ability to give signed informed consent

- Karnofsky Performance Status (KPS) at least 70

Exclusion Criteria:

- Placement of Gliadel wafers

- Participation in another investigational trial

- Active treatment of another malignancy
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT03477513      |      Link to official Clinicaltrials.gov listing
Locations
Philadelphia, Pennsylvania
Facility: Abramson Cancer Center of the University of Pennsylvania
Investigator: Robert Lustig, MD
Contact: Robert Lustig, MD Phone: 855-216-0098
Click HERE to send email to this center




Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740